Last $62.49 USD
Change Today -0.132 / -0.21%
Volume 1.9M
LLY On Other Exchanges
Symbol
Exchange
New York
Mexico
SIX Swiss Ex
Sao Paulo
EN Paris
Frankfurt
As of 3:22 PM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

eli lilly & co (LLY) Snapshot

Open
$62.13
Previous Close
$62.62
Day High
$62.71
Day Low
$62.00
52 Week High
06/30/14 - $63.38
52 Week Low
10/8/13 - $47.53
Market Cap
69.9B
Average Volume 10 Days
3.9M
EPS TTM
$3.69
Shares Outstanding
1.1B
EX-Date
08/13/14
P/E TM
16.9x
Dividend
$1.96
Dividend Yield
3.14%
Current Stock Chart for ELI LILLY & CO (LLY)

eli lilly & co (LLY) Details

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men at high risk of fracture; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency, as well as provides anti-infectives. Its neuroscience products treat major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; attention-deficit hyperactivity disorder; depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and brain imaging of beta-amyloid neuritic plaques. The company’s oncology products treat pancreatic, metastatic breast, non-small cell lung, ovarian, bladder, colorectal, and head and neck cancers, as well as malignant pleural mesothelioma; and cardiovascular products are used to treat erectile dysfunction and benign prostatic hyperplasia, and pulmonary arterial hypertension, as well as to reduce thrombotic cardiovascular events and as adjunct to percutaneous coronary intervention. In addition, it provides animal health products, such as cattle feed additives; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; leanness and performance enhancers for swine and cattle; protein supplements to enhance milk productivity in dairy cows; anticoccidial agents; and products that prevent flea infestations on dogs, kills fleas, prevent heartworm disease, and control intestinal parasite infections. The company distributes its products through independent wholesale distributors and directly to pharmacies. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

37,925 Employees
Last Reported Date: 02/19/14
Founded in 1876

eli lilly & co (LLY) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $1.0M
Executive Vice President of Science & Technol...
Total Annual Compensation: $1.0M
Senior Vice President and President of Lilly ...
Total Annual Compensation: $680.7K
Senior Vice President and General Counsel
Total Annual Compensation: $765.0K
Compensation as of Fiscal Year 2013.

eli lilly & co (LLY) Key Developments

Sanofi Files Lawsuit Against Eli Lilly

Sanofi has lodged a lawsuit before the US District Court in Wilmington, Delaware, against Eli Lilly for alleged infringement of seven patents related to Sanofi's Lantus (insulin glargine) and devices used to deliver it. Sanofi's filing follows a first lawsuit filed in January before the District Court for the District of Delaware against Eli Lilly concerning the alleged patent infringement of four patents linked to Lantus. The lawsuits give Sanofi the possibility to buy some time and to significantly delay the launch of Eli Lilly's rival product Abasria (insulin glargine) on the US market.

Yabao Pharma and Eli Lilly to Jointly Develop Diabetes Treatment

Yabao Pharmaceutical has entered into a strategic partnership with Eli Lilly and Company to jointly develop Lilly's glucokinase activator (GKA), LY2608204, which has completed Phase I studies in the US in addition to extensive pre-clinical development. GKAs have the potential to differentiate from other anti-diabetic agents by exerting two potentially beneficial actions: promoting insulin secretion and decreasing glucose production by the liver. As a result, GKAs may exert powerful anti-hyperglycemic effects, even in patients who are relatively unresponsive to other oral drugs. As part of the deal, Yabao will secure rights to develop and commercialize the GKA compound in China and Lilly retains rights in all other markets. Both the firms will collaborate to determine a strategic development plan for China, while Yabao will initially be responsible to perform and fund all development, with Lilly having future buy-in options for China.

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly Announce Encouraging Results from Phase III Diabetes Trials

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company have announced results from two Phase III clinical trials which demonstrated that the investigational combination tablet of empagliflozin and linagliptin reduced blood glucose levels in adults with type 2 diabetes, or T2D. The 24-week primary findings of these two 52-week trials compared the combination of empagliflozin and linagliptin with empagliflozin or linagliptin alone in patients with T2D and moderately elevated blood glucose levels consistent with what is often seen in clinical practice. If approved, this investigational combination would bring together the distinct mechanisms of action of a sodium glucose co-transporter-2 (SGLT2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor for the first time in one tablet. SGLT2 inhibitors remove excess glucose through the urine by blocking blood glucose re-absorption in the kidney. DPP-4 inhibitors work by increasing hormones that stimulate the pancreas to produce more insulin and stimulate the liver to produce less glucose. This 52-week study of 686 randomized adults with T2D examined the change from baseline of hemoglobin A1C (a measure of average blood glucose over the past two to three months) at 24 weeks. Adults in this study had a mean baseline A1C of 8.0%. Both empagliflozin/linagliptin combination doses showed statistically significant reductions in A1C vs. the empagliflozin component dose or linagliptin alone. Statistically significantly more adults who had A1C levels of 7.0% or more at baseline achieved A1C levels less than 7.0% after 24 weeks with both doses of the empagliflozin/linagliptin combination versus either empagliflozin or linagliptin alone. For adults who had A1C levels of 8.5% or greater at baseline, the following reductions in A1C were seen. The empagliflozin 25 mg/linagliptin 5 mg combination reduced A1C by 1.8%, compared with 1.2 % for empagliflozin 25 mg. The empagliflozin 10 mg/linagliptin 5 mg combination reduced A1C by 1.6%, compared with 1.3% for empagliflozin 10 mg. Linagliptin 5 mg alone reduced A1C by 1.0%. The empagliflozin/linagliptin combinations resulted in weight loss similar to that of empagliflozin monotherapy. Adverse events (AEs) were reported in 54.7% of subjects on the empagliflozin 25 mg/linagliptin 5 mg combination, 54.4% of subjects on the empagliflozin 10 mg/linagliptin 5 mg combination, 63.1% of subjects on empagliflozin 25 mg, 57.1% of subjects on empagliflozin 10 mg and 54.5% of subjects on linagliptin 5 mg. Confirmed hypoglycemic AEs were reported in two subjects each on the empagliflozin 25 mg/linagliptin 5 mg combination (1.5%), the empagliflozin 10 mg/linagliptin 5 mg combination (1.5%), empagliflozin 10 mg (1.4%) and linagliptin 5 mg (1.5%), and four on empagliflozin 25 mg (2.8%); none required assistance. This 52-week study of 677 adults with T2D who were treatment-naive examined the reduction in A1C from baseline at 24 weeks. As with the metformin study, adults in this study had moderate hyperglycemia (mean A1C of 8.0%) at baseline. A1C reduction with the empagliflozin 25 mg/linagliptin 5 mg combination was not statistically significantly greater than that of empagliflozin 25 mg. A1C reduction with the empagliflozin 10 mg/linagliptin 5 mg combination was significantly greater than that of empagliflozin 10 mg alone. Compared with linagliptin 5 mg, both combination doses significantly reduced A1C and body weight. Significantly more adults who had A1C levels of 7.0% or more at baseline achieved A1C levels less than 7.0% after 24 weeks with both doses of the empagliflozin/linagliptin combination versus the empagliflozin component dose or linagliptin alone. AEs were reported in 58.8% of subjects on the empagliflozin 25 mg/linagliptin 5 mg combination, 63.2% of subjects on the empagliflozin 10 mg/linagliptin 5 mg combination, 57.8% of subjects on empagliflozin 25 mg, 62.2% of subjects on empagliflozin 10 mg and 64.4% of subjects on linagliptin 5 mg. Confirmed hypoglycemic AEs were reported in two subjects (1.5%) on empagliflozin 25 mg and one each (0.7%) on empagliflozin 10 mg and linagliptin 5 mg; none required assistance. No confirmed hypoglycemic events were reported for patients randomized to empagliflozin/linagliptin combinations.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLY:US $62.49 USD -0.132

LLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $41.09 USD -0.18
AbbVie Inc $55.57 USD +0.56
Amgen Inc $118.50 USD -1.07
Bristol-Myers Squibb Co $48.47 USD +0.55
Teva Pharmaceutical Industries Ltd $54.09 USD +0.221
View Industry Companies
 

Industry Analysis

LLY

Industry Average

Valuation LLY Industry Range
Price/Earnings 17.5x
Price/Sales 3.0x
Price/Book 3.7x
Price/Cash Flow 18.1x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELI LILLY & CO, please visit www.lilly.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.